O

Onxeo SA
PAR:ALONX

Watchlist Manager
Onxeo SA
PAR:ALONX
Watchlist
Price: 0.272 EUR 0.74% Market Closed
Market Cap: 30.2m EUR

Operating Margin
Onxeo SA

-1 186.1%
Current
-597%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 186.1%
=
Operating Profit
-17.1m
/
Revenue
1.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
Onxeo SA
PAR:ALONX
30.2m EUR
-1 186%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
336.1B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.8B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
131.1B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Onxeo SA
Glance View

Market Cap
30.2m EUR
Industry
Biotechnology

Onxeo SA is a is a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2005-07-12. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.

ALONX Intrinsic Value
Not Available
O
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 186.1%
=
Operating Profit
-17.1m
/
Revenue
1.4m
What is the Operating Margin of Onxeo SA?

Based on Onxeo SA's most recent financial statements, the company has Operating Margin of -1 186.1%.

Back to Top